Ipragliozin, a sodium-glucose co-transporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure

Trial Profile

Ipragliozin, a sodium-glucose co-transporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2016

At a glance

  • Drugs Ipragliflozin (Primary)
  • Indications Heart failure; Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 23 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top